Zacks Investment Research upgraded shares of CHELSEA THERAP (CHTP) from NEUTRAL to OUTPERFORM on August 13, 2012, with a target price of $1.10.
Chelsea Therapeutics is a biopharmaceutical development company that acquires and develops innovative products for the treatment of a variety of human diseases. Chelsea develops technologies that address important unmet medical needs or offer improved, cost-effective alternatives to current methods of treatment. Chelsea concentrates its efforts on acquiring and developing technologies for the treatment of rheumatoid arthritis, psoriasis, cancer and other immunological disorders.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on CHELSEA THERAP (CHTP),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment